This article is part of a larger series on the risks of molnupiravir. For a summary of the risks at the level of the individual, see here, and for an overview of the risks on a societal level, see ...

The antiviral molnupiravir may be shaping the evolution of the virus behind COVID-19, but we still don't know what this means for transmission or the emergence of variants. When you purchase through ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The antiviral reduced the risk for severe symptoms of ...

Molnupiravir (taken as an 800mg dose twice daily for five days) does not reduce hospital admissions or deaths in vaccinated adults with COVID-19 infection who are at higher risk of mortality, ...

A new study suggests that the antiviral Molnupiravir may “paradoxically” be driving COVID-19 mutations, creating variants of concern. What is going on? It is all about molnupiravir’s mode of action ...

A new study currently available on the Research Square* preprint server has pointed out that molnupiravir treatment increases the ratio of transition to transversion mutations in coronavirus disease ...

The antiviral drug molnupiravir (Lagevrio) slashed the risk of death from COVID-19 in half when given early to older adults. It also lowered all-cause deaths among older adults in the Czech Republic ...

Patients with COVID-19 taking molnupiravir or nirmatrelvir-ritonavir rarely have viral rebound, and rebound is not associated with increased mortality risk, according to a study published online Dec.

There are currently two approved COVID-19 treatments that can be taken orally: nirmatrelvir-ritonavir (known as Paxlovid and developed by Pfizer) and Merck’s molnupiravir. They have both been shown to ...